- Home
- FBYD vs CRDF Comparison
FBYD vs CRDF Comparison
Compare FBYD & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBYD
- CRDF
- Stock Information
- Founded
- FBYD 2021
- CRDF 1999
- Country
- FBYD United States
- CRDF United States
- Employees
- FBYD N/A
- CRDF N/A
- Industry
- FBYD
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBYD
- CRDF Health Care
- Exchange
- FBYD Nasdaq
- CRDF Nasdaq
- Market Cap
- FBYD 224.6M
- CRDF 233.5M
- IPO Year
- FBYD N/A
- CRDF N/A
- Fundamental
- Price
- FBYD $7.62
- CRDF $3.97
- Analyst Decision
- FBYD
- CRDF Strong Buy
- Analyst Count
- FBYD 0
- CRDF 6
- Target Price
- FBYD N/A
- CRDF $11.92
- AVG Volume (30 Days)
- FBYD 9.7K
- CRDF 1.6M
- Earning Date
- FBYD 08-12-2025
- CRDF 08-07-2025
- Dividend Yield
- FBYD N/A
- CRDF N/A
- EPS Growth
- FBYD N/A
- CRDF N/A
- EPS
- FBYD N/A
- CRDF N/A
- Revenue
- FBYD $6,937,000.00
- CRDF $587,000.00
- Revenue This Year
- FBYD N/A
- CRDF N/A
- Revenue Next Year
- FBYD N/A
- CRDF N/A
- P/E Ratio
- FBYD $491.11
- CRDF N/A
- Revenue Growth
- FBYD N/A
- CRDF N/A
- 52 Week Low
- FBYD $3.62
- CRDF $2.01
- 52 Week High
- FBYD $13.25
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- FBYD 63.89
- CRDF 52.55
- Support Level
- FBYD $7.08
- CRDF $3.73
- Resistance Level
- FBYD $8.16
- CRDF $4.52
- Average True Range (ATR)
- FBYD 0.60
- CRDF 0.30
- MACD
- FBYD 0.16
- CRDF -0.02
- Stochastic Oscillator
- FBYD 72.01
- CRDF 30.59
About FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has four operating segments, Falcon's Creative Group, PDP, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.